Pebody R, Whitaker H, Zhao H, et al. - Given 2018/19 represents the first season of the introduction of a newly licensed adjuvanted influenza vaccine (aTIV) in England for adults 65 years or older, who were earlier administered standard-dose, non-adjuvanted vaccine, obtaining uptake levels > 70%, usually with poor effectiveness, researchers analyzed this population to report the end-of-season adjusted vaccine effectiveness (aVE) against laboratory verified influenza hospitalisation. Overall 428 cases (influenza confirmed hospitalisations) and 1,013 controls (influenza negative hospitalisations who were 65 years or more) were analyzed. As per findings, end-of-season any-influenza aVE against hospitalisation was estimated to be 53.4%. Against influenza A(H1N1)pdm09 and against influenza A(H3N2), the aVE was estimated to be 64.8% and 39.3%, respectively. For the estimation of influenza B VE, the available data were not sufficient. For all influenza, influenza A(H1N1)pdm09 and influenza A(H3N2), the aVE for aTIV was estimated to be 53.8%; 65.9% and 39.5% respectively. In the elderly, aTIV offered significant influenza VE, which was most notable against influenza A(H1N1)pdm09, but also against A(H3N2).